Stocklytics Platform
Asset logo for symbol ALLO
Allogene Therapeutics
ALLO46
$2.83arrow_drop_down7.21%-$0.22
Penny Stock
Asset logo for symbol ALLO
ALLO46

$2.83

arrow_drop_down7.21%

Performance History

Chart placeholder
Key Stats
Open$3.07
Prev. Close$3.05
EPS-1.78
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$636.79M
PE Ratio-
LOWHIGH
Day Range2.81
3.07
52 Week Range2.01
5.78
Ratios
Revenue-
EBITDA Margin %-
EPS-1.78

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$857.46
Perf. (24h)
arrow_drop_up1.00%$8.56
Market Cap$764.35B
Price$565.33
Perf. (24h)
arrow_drop_up0.17%$0.98
Market Cap$519.41B
Price$154.69
Perf. (24h)
arrow_drop_down0.46%-$0.73
Market Cap$374.04B
Price$125.77
Perf. (24h)
arrow_drop_up1.22%$1.52
Market Cap$314.70B

About Allogene Therapeutics (ALLO)

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David D. Chang M.D., Ph.D.
Headquarters
South San Francisco
Employees
359
Exchange
NASDAQ
add Allogene Therapeutics  to watchlist

Keep an eye on Allogene Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Allogene Therapeutics 's (ALLO) price per share?

The current price per share for Allogene Therapeutics (ALLO) is $2.83. The stock has seen a price change of -$0.22 recently, indicating a -7.21% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Allogene Therapeutics (ALLO)?

For Allogene Therapeutics (ALLO), the 52-week high is $5.78, which is 104.24% from the current price. The 52-week low is $2.01, the current price is 40.8% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Allogene Therapeutics (ALLO) a growth stock?

Allogene Therapeutics (ALLO) has shown an average price growth of 0.41% over the past three years. It has received a score of 6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Allogene Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Allogene Therapeutics (ALLO) stock price performance year to date (YTD)?

As of the latest data, Allogene Therapeutics (ALLO) has a year-to-date price change of -21.82%. Over the past month, the stock has experienced a price change of 15.98%. Over the last three months, the change has been -18.44%. Over the past six months, the figure is -8.41%. Looking at a longer horizon, the five-year price change stands at -89.9%.

help
Is Allogene Therapeutics (ALLO) a profitable company?

Allogene Therapeutics (ALLO) has a net income of -$327.26M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -315.93K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$314.49M. Furthermore, the EBITDA is -$270.66M.

help
What is the market capitalization of Allogene Therapeutics (ALLO)?

Allogene Therapeutics (ALLO) has a market capitalization of $636.79M. The average daily trading volume is 3.48M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level